The prospective economic impact of once-monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.

CONCLUSION: Over 12 months, pharmacy costs associated with switching patients from OAAs to PP1M were offset by reduced relapse rates and schizophrenia-related healthcare expenditures, with earlier use of PP1M projected to generate greater cost savings. PMID: 30526125 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research

Related Links:

EditorialE. Maggioni, M. Bellani, A. C. Altamura, P. Brambilla,Epidemiology and Psychiatric Sciences,Volume 25 Issue 04, pp 312-316Abstract
Source: Epidemiology and Psychiatric Sciences - Category: Epidemiology Source Type: research
Research ArticlesSoumaya Bourgou, Soumeyya Halayem, Isabelle Amado, Racha Triki, Marie Chantal Bourdel, Nicolas Franck, Marie Odile Krebs, Karim Tabbane, Asma Bouden,Acta Neuropsychiatrica,Volume 28 Issue 04, pp 232-238Abstract
Source: Acta Neuropsychiatrica - Category: Neurology Source Type: research
CONCLUSION: It was concluded that oral administration of LH-SLNs in rats improved the bioavailability of LH via lymphatic uptake along with improved therapeutic effect in MK-801 induced schizophrenia model in rats. PMID: 30880488 [PubMed - as supplied by publisher]
Source: Drug Development and Industrial Pharmacy - Category: Drugs & Pharmacology Tags: Drug Dev Ind Pharm Source Type: research
This study aims to develop an effective dynamic thresholding brain networks method to diagnose schizophrenia.MethodsIn this study, we proposed a time-varying window length DFC method based on dynamic time warping to construct brain functional networks. To further eliminate the influence of spurious connections caused by noise, orthogonal minimum spanning tree was applied in these networks to generate time-varying window length dynamic thresholding FC (TVWDTFC) networks. To validate the effectiveness of our proposed method, experiments were conducted on a dataset, which including 56 individuals with schizophrenia and 74 hea...
Source: Artificial Intelligence in Medicine - Category: Bioinformatics Source Type: research
Conditions:   Schizophrenia;   Schizoaffective Disorder Interventions:   Device: Active anodal tDCS;   Device: Sham tDCS Sponsor:   The University of Texas at Dallas Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Schizophrenia;   Major Depressive Disorder;   Bi-Polar Disorder;   Schizo Affective Disorder Intervention:   Combination Product: ABILIFY MYCITE Sponsors:   Durham VA Medical Center;   Otsuka Pharmaceutical Development and Commercialization, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Consumer demand for cannabidiol (CBD) oil has increased, with growing sales from dispensaries because of the alleged medicinal benefits. Although studies examining the specific therapeutic effects of CBD are increasing, clinical data do not support the popular uses of CBD for Parkinson disease, schizophrenia, cancer palliation and treatment, chronic pain and spasticity, depression, anxiety disorder, insomnia, and inflammation. PMID: 30880812 [PubMed - in process]
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) Researchers used C. elegans as an animal model to investigate the importance of certain human genes for the treatment of schizophrenia.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
This study used Trust data to explore the proportions of ethnic groups accessing psychological therapy as a proportion of all patients supported by the Trust, as well as their outcomes within broad diagnostic clusters.ResultsCompared to proportions in the local population, there were significantly more White/White British patients and significantly fewer patients from ‘other ethnic groups’ in the Trust (p 
Source: Journal of Racial and Ethnic Health Disparities - Category: International Medicine & Public Health Source Type: research
ConclusionCoadministration with rifampin decreased total systemic exposure (based on AUC∞) of olanzapine and samidorphan by 48% and 73%, respectively.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Invega | Invega Sustenna | Medicaid | Research | Schizophrenia | Study